Physician profile

Anthony Baroni

Hospitalist · Pittsburgh, PA

NPI 1578541009

$534.51

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$221.45

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $145.94 2020-2024 Xarelto
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $130.93 2023 Lifevest
E.R. Squibb & Sons, L.L.C. $92.04 2019-2020
Glaxosmithkline, LLC. $46.54 2019-2023 Trelegy Ellipta
Novartis Pharmaceuticals Corporation $45.70 2022
Horizon Therapeutics Plc $30.63 2023 Krystexxa
Boehringer Ingelheim Pharmaceuticals, INC. $28.39 2022
Abbvie INC. $14.34 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anthony Baroni

$534.51

in general payments reported 2019-2025

Years
2019-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/977701/anthony-baroni

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.